Zobrazeno 1 - 2
of 2
pro vyhledávání: '"C K, Yannakou"'
Autor:
Stanley Cheung, H.P. Miskin, Tomasz Wróbel, Owen A. O'Connor, Krzysztof Giannopoulos, Wojciech Jurczak, C. K Yannakou, C.Y. Cheah, A. D Ricart, Nicholas Wickham, J. P. Tang, M. Lasica, Katharine L Lewis, Jan Walewski, Constantine S. Tam, E. Normant, M. Długosz-Danecka
Publikováno v:
Hematological Oncology. 39
Introduction: TG-1701 is a selective, covalent BTK inhibitor administered once daily (QD). Both the “U2” combination (anti-CD20 mAb ublituximab + the PI3Kδ-CK1ϵ inhibitor umbralisib) and BTK inhibition are highly active in treatment-naive (TN)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1e1987bcf5fa485661ed4bf8db09cf5f
https://doi.org/10.1002/hon.148_2880
https://doi.org/10.1002/hon.148_2880
Autor:
S, Fleming, C K, Yannakou, G M, Haeusler, J, Clark, A, Grigg, C H, Heath, A, Bajel, S J, van Hal, S C, Chen, S T, Milliken, C O, Morrissey, C S, Tam, J, Szer, R, Weinkove, M A, Slavin
Publikováno v:
Internal medicine journal. 44(12b)
There is a strong argument for the use of antifungal prophylaxis in high-risk patients given the significant mortality associated with invasive fungal disease, the late identification of these infections, and the availability of safe and well-tolerat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::29aadae1746dce52eba72fbbafe4476f
https://pubmed.ncbi.nlm.nih.gov/25482741
https://pubmed.ncbi.nlm.nih.gov/25482741